# Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia

> **NCT02778906** · PHASE3 · COMPLETED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 98 (actual)

## Conditions studied

- Arthralgia
- Arthritis

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02778906
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2020-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02778906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02778906, "Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02778906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*